Top Mid Cap Companies To Invest In Right Now

On Thursday after the market closed, mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) reported earnings and was slipping in after hours trading, meaning its worth taking a closer look at those earnings along with the performance of potential semiconductor benchmarks like the SPDR S&P Semiconductor ETF (NYSEARCA: XSD), iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) and Direxion Daily Semiconductor Bull 3X Shares (NYSEARCA: SOXL). In case you aren�� familiar with the term fabless semiconductor, it�� a�business�model that involves the�outsourcing the manufacturing of silicon wafers.�Most semiconductor companies are actually fabless because of the high cost of building�a facility and manufacturing fab. Therefore, fabless semiconductor companies can�concentrate on the design and marketing of chips while outsourcing the actual production to larger foundry companies.

Top 5 Consumer Service Companies For 2015: Peat Resources Ltd (PET)

Peat Resources Limited is a Canada-based, development-stage company. The Company is engaged in the exploration and development of peat properties in Newfoundland and Labrador (Newfoundland) and Ontario. During the fiscal year ended May 31, 2012, the Company had not generated any revenue from its operations. Advisors' Opinion:

• [By TaniaC]

  The Coca-Cola Company (KO) and its bottling partners in Mexico announced a joint, six-year investment of $8.2 billion at a ceremony commemorating the world's largest food-grade polyethylene terephthalate (PET) bottle-to-bottle recycling plant. Coca-Cola began operations in Mexico 88 years ago.

Top Mid Cap Companies To Invest In Right Now: Forest Laboratories Inc (FRX)

Forest Laboratories, Inc. (Forest), incorporated on April 11, 1956, develops, manufactures and sells branded forms of ethical drug products, most of which requires a physician's prescription. The Company also focuses on the development and introduction of new products, including products developed in collaboration with licensing partners. Its products include those developed by the Company and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. The Company�� principal products include Lexapro, its selective serotonin reuptake inhibitor (SSRI) for the treatment of major depressive disorder (MDD) in adults and adolescents and generalized anxiety disorder (GAD) in adults; Namenda, its N-methyl-D-Aspartate (NMDA) antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; Savella, its selective serotonin and norepinephrine reuptake inhibitor (SNRI) for the management of fibromyalgia and its newest marketed product Teflaro, a broad-spectrum hospital-based injectable cephalosporin antibiotic for the treatment of adults with community-acquired bacterial pneumonia. On April 13, 2011, the Company acquired Clinical Data Inc. (Clinical Data), a specialty pharmaceutical company.

Aclidinium

In June 2011, the Company ahs submitted a New Drug Application (NDA) to the Food and Drug Administration (FDA) for aclidinium (aclidinium bromide), a long-acting antimuscarinic agent developed as an inhaled therapy for the maintenance treatment of chronic obstructive pulmonary disease (COPD). When given by inhalation, aclidinium leads to bronchodilation by inhibiting airway smooth muscle contraction. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Aclidinium is administered to patients using a multi-dose dry powder inhaler (MDPI). This inhaler was designed with a feedback system which, through a ��olored control window��and an a! udible click, helps confirm that the patient has inhaled correctly. It contains multiple doses of aclidinium, includes a visible dose-level indicator, and also incorporates features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.

Linaclotide

Linaclotide is being investigated for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation (CC). Linaclotide is an agonist of the guanylate cyclase type-C receptor found in the intestine and acts by a mechanism. Linaclotide increases fluid secretions leading to increased bowel movement frequency and reduces abdominal pain. Linaclotide is administered orally but acts locally in the intestine with no measurable systemic exposure at therapeutic doses and is intended for once-daily administration.

Viibryd

As a result of its acquisition of Clinical Data, Inc. (Clinical Data) completed in April 2011, the Company obtained worldwide rights to develop and market Viibryd (vilazodone HCl) a selective serotonin reuptake inhibitor and a 5-HT1A receptor partial agonist developed by Clinical Data for the treatment of adults with major depressive disorder (MDD). Viibryd became available to patients during the June 2011 quarter and was formally launched in the U.S. in late August 2011.

Daliresp

In February 2011, the Company received approval from the United States Food and Drug Administration (FDA) for the marketing of Daliresp (roflumilast). Daliresp is once-daily, orally administered, selective phosphodiesterase 4 (PDE4) enzyme inhibitor, developed by its partner, Nycomed GmbH (Nycomed), as a treatment to reduce the risk of exacerbations in patients with severe chronic obstructive pulmonary disease (COPD) associated with chronic bronchitis and a history of exacerbations.

Namenda

Namenda (memantine HCl) is an N-methyl-D-Aspartate (NMDA) receptor agonist for the treatmen! t of mode! rate and severe Alzheimer�� disease. In June 2010, Namenda XR was approved by the FDA for the treatment of moderate to severe dementia of the Alzheimer�� type. Namenda XR is a 28 milligrams once-daily extended-release formulation of Namenda. The Company has obtained the exclusive rights to develop and market memantine in the United States by license agreement with Merz Pharma GmbH & Co. KgaA (Merz) of Germany, the originator of the product.

Bystolic

Bystolic is a beta-1 selective beta-blocker with vasodilating properties. Bystolic decreases heart rate and myocardial contractility and suppresses rennin activity. The Company licensed exclusive United States and Canadian rights to Bystolic from Mylan Inc. (Mylan).

Savella

Savella (milnacipran HCl) is the Company�� selective serotonin and norepinephrine inhibitor (SNRI) for the management of fibromyalgia. Fibromyalgia is a chronic condition characterized by widespread pain and decreased physical function. The Company licensed the United States and Canadian rights to develop and commercialize Savella from Cypress Bioscience, Inc. (Cypress). Its license agreement includes two patents covering the use of Savella for the management of fibromyalgia.

Teflaro

In October 2010, the Company received marketing approval from the FDA for Teflaro (ceftaroline) for the treatment of adults with community-acquired bacterial pneumonia, including cases caused by Streptococcus pneumoniae bacteremia and with acute bacterial skin and skin structure infections, including cases caused by methicillin-resistant Staphylococcus aureus. Teflaro is a spectrum, hospital-based injectable cephalosporin antibiotic with activity against Gram-positive bacteria and common Gram-negative bacteria. Teflaro is a member of the cephalosporin class of antibiotics. The worldwide rights (excluding Japan) to Teflaro are in-licensed on an exclusive basis from Takeda Pharmaceutical Company (Takeda). Teflaro is als! o covered! by two United States patents that relate to the ceftaroline formulation that expire in 2021 and that may provide additional exclusivity.

Avibactam

Avibactam is designed to be co-administered with select antibiotics to enhance their spectrum of activity. The Company received the exclusive rights to administer avibactam with ceftaroline as a combination product in North America. Avibactam is a beta-lactamase inhibitor designed to be co-administered with select antibiotics to enhance their spectrum of activity by overcoming beta-lactamase-related antibacterial resistance.

Lexapro

Lexapro�� is a SSRI for the treatment of MDD in adults and adolescents and GAD in adults. Lexapro�� (escitalopram oxalate) single isomer version of citalopram HBr, for the treatment of MDD in adults and adolescents and GAD in adults.

Cariprazine

Cariprazine is an oral D2/D3 partial agonist. Cariprazine is also undergoing Phase III trials for schizophrenia and acute mania associated with bipolar depression, bipolar depression and as an adjunct treatment for MDD.

Levomilnacipran

Levomilnacipran is a once-daily, selective norepinephrine and serotonin reuptake inhibitor, two neurotransmitters known to play an essential role in regulating mood, and is being developed for the treatment of MDD.

GRT 6005

In December 2010, the Company entered into a license agreement with Grunenthal GmbH for the co-development and commercialization of GRT 6005 and its follow-on compound GRT 6006, small molecule analgesic compounds being developed by Grunenthal for the treatment of moderate to severe chronic pain. GRT 6005 and GRT 6006 are compounds with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions. GRT 6005 has completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase II studies planned prior to initiation of Phase III s! tudies.

TTP399

In June 2010, the Company entered into a license agreement with TransTech Pharma, Inc. (TransTech) for the development and commercialization of TTP399, a functionally liver selective glucokinase activator (GKA) discovered and developed by TransTech for the treatment of Type II diabetes. Early Phase I testing suggests that pharmacological enhancement of glucokinase activity may lower blood glucose in diabetic patients.

Azimilide

In April 2011, the Company entered into an agreement with Blue Ash Therapeutics, LLC (Blue Ash) pursuant to which it acquired the worldwide rights to azimilide, a class III antiarrhythmic agent developed by Proctor & Gamble Pharmaceuticals. Based on its mechanism of action and results of clinical trials, azimilide was determined to be suited for use in patients with a history of life-threatening ventricular arrhythmias and who have an implantable cardioverter defibrillator. In 2010, the FDA agreed to one additional Phase III study to support a regulatory submission for azimilide in the U.S.

RGH-618

RGH-618 involves a series of compounds that target metabotropic glutamate receptors and are agonists, which represent potential agents for the treatment of anxiety, depression and other central nervous system (CNS) conditions. In March 2012, the Company initiated a Phase I study in healthy volunteers of RGH-618.

Advisors' Opinion:

• [By David Williamson and Michael Douglass]

  The�Science Translational Medicine�journal recently published research about the generic antidepressant�citalopram, which was�developed�by Forest�Laboratories (NYSE: FRX  ) �under the brand name Celexa, as a potential way to help slow down the�development�of Alzheimer's disease.

• [By Johanna Bennett]

  Forest Laboratories (FRX) surged 9.7% to close at $56.32, marking the biggest gain in the S&P 500. The drug maker unveiled plans to trim $500 million in costs, and spend at least $400 million buying back its stock.

Top Mid Cap Companies To Invest In Right Now: BancorpSouth Inc (BXS)

BancorpSouth, Inc., incorporated on February 17, 1982, is a financial holding company. Through its principal bank subsidiary, BancorpSouth Bank (the Bank), the Company conducts commercial banking and financial services operations in Mississippi, Tennessee, Alabama, Arkansas, Texas, Louisiana, Florida, Missouri and Illinois. As of December 31, 2012, the Company and its subsidiaries had total deposits of $11.1 billion. The Bank conducts a general commercial banking, trust and insurance business through 284 offices in Mississippi, Tennessee, Alabama, Arkansas, Texas, Louisiana, Florida, Missouri and Illinois. The Bank and its subsidiaries provide a range of financial services to individuals and small-to-medium size businesses. On July 2, 2012, the Company purchased certain assets of The Securance Group, Inc.

The Bank operates investment services and insurance agency subsidiaries, which engage in investment brokerage services and sales of other insurance products. The Bank�� trust department offers a range of services, including personal trust and estate services, certain employee benefit accounts and plans, including individual retirement accounts, and limited corporate trust functions.

Lending Activities

The Bank�� lending activities include both commercial and consumer loans. The Bank offers a range of commercial loan services including term loans, lines of credit, equipment and receivable financing and agricultural loans. A range of short-to-medium term commercial loans, both secured and unsecured, are made available to businesses for working capital (including inventory and receivables), business expansion (including acquisition and development of real estate and improvements), and the purchase of equipment and machinery. The Bank also makes construction loans to real estate developers for the acquisition, development and construction of residential subdivisions.

The Bank�� lending activities consists of the origination of fixed and adjustable! rate residential mortgage loans secured by owner-occupied property located in the Bank�� primary market areas. In addition, the Bank offers construction loans, second mortgage loans and home equity lines of credit. The Bank finances the construction of individual, owner-occupied houses on the basis of written underwriting and construction loan management guidelines.

The Bank makes residential construction loans to individuals who intend to erect owner-occupied housing on a purchased parcel of real estate. The Bank sells its mortgage loans with terms of 15 years or more in the secondary market and either retains or releases the right to service those loans. Non-residential consumer loans made by the Bank include loans for automobiles, recreation vehicles, boats, personal (secured and unsecured) and deposit account secured loans. The Bank also issues credit cards.

Investment Activities

As of December 31, 2012, the Company�� held-to-maturity and available-for-sale securities included the United States Government agency securities, taxable obligations of states and political subdivisions, tax-exempt obligations of states and political subdivisions, government agency issued residential mortgage-backed securities, government agency issued commercial mortgage-backed securities, collateralized debt obligations and other securities. As of December 31, 2011, the Company�� available-for-sale securities totaled $ 2.4 billion. Investments in tax-exempt securities totaled $455.1 million as of December 31, 2012.

Source of Funds

Deposits originating within the communities served by the Bank are the primary source of funding. As of December 31, 2012, the Company and its subsidiaries had total deposits of $ 11.1 million. The Bank offered deposits, such as noninterest bearing demand deposits, interest bearing demand deposits, savings deposits and other time deposits. The Company had federal funds purchased and securities sold under agreement to repurc! hase of $! 414.6 million as of December 31, 2012.

Subsidiary Activities

The Bank�� insurance service subsidiary serves as an agent in the sale of title insurance, commercial lines of insurance and a full line of property and casualty, life, health and employee benefits products and services and operates in Mississippi, Tennessee, Alabama, Arkansas, Texas, Louisiana, Missouri and Illinois. The Bank�� investment services subsidiary provides brokerage, investment advisory and asset management services and operates in certain communities in Mississippi, Tennessee, Alabama, Arkansas, Louisiana, Texas, Florida and Missouri.

Advisors' Opinion:

• [By Vera Yuan]

  BancorpSouth (BXS) fell over 18 percent and cost the portfolio 31 basis points of performance. The company announced plans to delay several announced acquisitions as increased scrutiny by the Federal Reserve and the Consumer Financial Protection Bureau (CFPB) concerning BSA/AML (Bank Secrecy Act and anti-money laundering) is ongoing and the reviews will need to be completed before the acquisitions are allowed to proceed. This caused earnings reductions due to delayed deal accretion. We have seen this issue pop up at several other institutions and while it's unfortunate, we feel this is not a specific issue germane to only BXS but rather the result of increased scrutiny from Washington DC regulators concerned with money laundering. Management is complying with all policy and procedural change requests and hopes to have the matter resolved in the near future.From John Keeley (Trades, Portfolio)�� KEELEY All Cap Value Fund Q3 2014 Commentary.Also check out: John Keeley Undervalued Stocks John Keeley Top Growth Companies John Keeley High Yield stocks, and Stocks that John Keeley keeps buying Currently 0.00/512345

  Rating: 0.0/5 (0 votes)

Top Mid Cap Companies To Invest In Right Now: Aristocrat Group Corp (ASCC)

ARISTOCRAT GROUP CORP. (AGC), incorporated on July 20, 2011, is a development-stage company. The Company has limited business operations. The development of its business has been limited to organizational matters, the preparation of its business plan, and the preparation of the financial statements and other information. Through Prenatal-Postpartum Supercare Centers, the Company is focused on to provide education services, health and fitness services, and emotional well-being spa services with the ability to purchase products designed especially for women who are in any phase of the childbearing process from planning a family through the newborn�� first year of life. As of July 25, 2011, the Company had not generated revenue.

The Company focused to engage certified childbirth educators and lactation consultants to provide on-site instructional services and educational expertise. Yoga Masters, licensed professional masseuses, nutritionists, licensed estheticians, as well as licensed professional therapists and certified fitness instructors will be engaged to provide their specific services. The Company is focused to offer a variety of educational and fitness and spa services with varying fees. The Company is focused to sell products designed for the expecting or new mother, as well as infant/toddler items. These products are focused to be sold through the Prenatal-Postpartum Supercare Center and on its Website, including maternity and infant products, nutritional, health and beauty products, and items regarding fitness and physical and emotional well-being. The Website focused to offer Education, Ask An Expert and On-line Communities (Chat Rooms)

The Company competes with R��Us, Toys R��Us, Wal-Mart, Curves for Women and Shapes for Women.

Advisors' Opinion:

• [By CRWE]

  Today, ASCC surged (+11.11%) up +0.060 at $.600 with 83,411 shares in play thus far (ref. google finance Delayed: 12:23PM EDT June 27, 2013).

  As part of the big promotional push planned for the upcoming release of RWB Ultra-Premium Handcrafted Vodka, Luxuria Brands��he brand management division of the Aristocrat Group Corp. is investigating high-profile sponsorship opportunities in professional sports.

  The company is gearing up to compete in the $21 billion U.S. spirits industry, in which many top brands grow their consumer loyalty with sports sponsorships.

Top Mid Cap Companies To Invest In Right Now: Global Digital Creations Holdings Ltd (GDC)

Global Digital Creations Holdings Limited is an investment holding company. Through its subsidiaries, the Company operates in three segments: computer graphics (CG) and production segment, which includes CG creation, production and exhibition of motion pictures and production of television series and movies, as well as property rental income; CG training courses segment, engaged in the provision of CG and animation training, and cultural park segment, engaged in the media entertainment and related commercial property development. The Company�� subsidiaries include GDC Holdings Limited, GDC Asset Management Limited, GDC China Limited, GDC Digital Cinema Network Limited, GDC Digital Cinema Network Limited, GDC International Limited and GDC Management Services Limited, among others. On September 6, 2011, it completed the disposal of interests in GDC Technology Limited and GDC Digital Cinema Network Limited. Advisors' Opinion:

• [By Barel Karsan]

  If you follow Genesis Land (GDC), your head may be spinning by now. It's almost every day now that the current board and the activists trying to take it over are claiming some sort of injustice permeated by the other side. (To watch this battle in real-time, sign up for filing notifications for GDC here.) But surely, behind all the "Our directors are superior to yours" puffery, there are some differences in how each group would run the company differently.